<DOC>
	<DOCNO>NCT01282398</DOCNO>
	<brief_summary>The purpose study determine whether simvastatin effective prevention progression porta hypertension compensate cirrhosis patient .</brief_summary>
	<brief_title>Study About Simvastatin Portal Hypertension Compensated Cirrhosis</brief_title>
	<detailed_description>Decompensation cirrhosis associate dramatic reduction survival . Progression portal hypertension ( PHT ) main determinant decompensation appear portal pressure gradient ( PPG ) â‰¥10mmHg ( clinically significant HTP ) . 40 % compensate cirrhotic patient mild PHT . However , progression disease 41 % develop clinically significant PHT . In cirrhosis , PHT result increase resistance blood flow , dynamic component due decrease nitric oxide ( NO ) bioavailability . In advanced disease increase portal venous inflow also contribute PHT . Beta-blockers useful compensated cirrhosis mild PHT . In early cirrhosis , vasodilator may adequate . Statins , drug inhibit activity HMG-CoA reductase , induce selective hepatic vasodilation due enhance bioavailability NO . Acutely , decrease hepatic resistance , long-term use statins decrease PPG without deleterious effect systemic circulation . This multicenter , randomize , double-blind placebo-controlled study aim assess whether treatment simvastatin may prevent progression mild PHT ( PPG 6 10 mmHg ) clinically significant PHT . Patients compensated cirrhosis , without previous decompensation , without esophageal varix risk PPG 6 10 mmHg include . The calculated sample size 80 patient duration study 4 year ( 2 year include follow-up least 2 year ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>Liver cirrhosis diagnose previous biopsy clinical , laboratory , ultrasound Portal hypertension gradient between6 mmHg and10 mmHg Absence esophageal gastric varix small esophageal varix without red sign Absence previous episode gastrointestinal hemorrhage , ascites , encephalopathy jaundice Written inform consent Age &lt; 18 &gt; 80 year , Presence history ascites , clinical ultrasound , Previous decompensation liver cirrhosis , ascites SBP , bleed varix , large varix , hepatic encephalopathy , jaundice , Thrombosis splenoportal , Hepatocellular carcinoma ; ChildPugh &gt; 7 point Any comorbidity lead restriction therapy / life expectancy &lt; 12 month Absolute contraindication treatment statins allergy Simvastatin ; Concomitant potent CYP3A4 inhibitor ( eg. , itraconazole , ketoconazole , protease inhibitor , HIV , erythromycin , clarithromycin , telithromycin nefazodone ) , Pretreatment ( &lt; 1 month ) simvastatin lipidlowering , Previous episodes rhabdomyolysis , Active alcoholic hepatitis , Refusal participate study informed consent claim ; Pretreatment beta blocker nitrate , endoscopic treatment varicose vein portosystemic derivation ; Pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>